FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival.
Also in this 8-page issue: Tony Hunter, Raymond DuBois win AACR Landon prizes.
Funding opportunities: ASCO breast cancer research award; Lustgarten Foundation prostate cancer research award; NCI program announcements available.
Trending Stories
- Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri - As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
